1 |
Sun GB, Sun X, Wang M, et al (2012). Oxidative stress suppression by luteolin-induced heme oxygenase-1 expression. Toxicol Appl Pharmacol, 265, 229-40.
DOI
ScienceOn
|
2 |
Pandurangan AK, Esa NM (2013). Dietary non-nutritive factors in targeting of regulatory molecules in colorectal cancer: an update. Asian Pac J Cancer Prev, 14, 5543-52.
DOI
ScienceOn
|
3 |
Shim G S, Manandhar S, Shin DH, Kim TH, Kwak MK (2009). Acquisition of doxorubicin resistance in ovarian carcinoma cells accompanies activation of the NRF2 pathway. Free Radic Biol Med, 47, 1619-31.
DOI
ScienceOn
|
4 |
Tang X, Wang H, Fan L, et al (2011). Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs. Free Radic Biol Med, 50, 1599-609.
DOI
ScienceOn
|
5 |
Wakabayashi N, Slocum SL, Skoko JJ, et al (2010). When NRF2 talks, who's listening? Antioxid Redox Signal, 13, 1649-63.
DOI
ScienceOn
|
6 |
Wang JH, Du JP, Zhang YH, et al (2011). Dynamic changes and surveillance function of prion protein expression in gastric cancer drug resistance. World J Gastroenterol, 17, 3986-93.
DOI
ScienceOn
|
7 |
Wang XJ, Hayes JD, Higgins LG, Wolf CR, Dinkova-Kostova AT (2010). Activation of the NRF2 signaling pathway by coppermediated redox cycling of para- and ortho-hydroquinones. Chem Biol, 17, 75-85.
DOI
ScienceOn
|
8 |
Wruck CJ, Claussen M, Fuhrmann G, et al (2007). Luteolin protects rat PC12 and C6 cells against MPP+ induced toxicity via an ERK dependent Keap1-Nrf2-ARE pathway. J Neural Transm Suppl, 72, 57-67.
DOI
|
9 |
Yoo NJ, Kim YR, Lee SH (2010). Expression of NRF2, a cytoprotective protein, in gastric carcinomas. APMIS, 118, 613-4.
|
10 |
Niture SK, Jaiswal AK (2012). Nrf2 protein up-regulates antiapoptotic protein Bcl-2 and prevents cellular apoptosis. J Biol Chem, 287, 9873-86.
DOI
|
11 |
Lin Y, Shi R, Wang X, Shen HM (2008). Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr Cancer Drug Targets, 8, 634-46.
DOI
|
12 |
Magesh S, Chen Y, Hu L (2012). Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents. Med Res Rev, 32, 687-726.
DOI
ScienceOn
|
13 |
Itoh K, Mimura J, Yamamoto M (2010). Discovery of the negative regulator of Nrf2, Keap1: a historical overview. Antioxid Redox Signal, 13, 1665-78.
DOI
ScienceOn
|
14 |
McMahon M, Itoh K, Yamamoto M, et al (2001). The Cap'n'Collar basic leucine zipper transcription factor Nrf2 (NF-E2 p45-related factor 2) controls both constitutive and inducible expression of intestinal detoxification and glutathione biosynthetic enzymes. Cancer Res, 61, 3299-307.
|
15 |
O'Connell M J, Walworth NC, Carr AM (2000). The G2-phase DNA-damage checkpoint. Trends Cell Biol, 10, 296-303.
DOI
ScienceOn
|
16 |
Kwak MK, Kensler TW (2010). Targeting NRF2 signaling for cancer chemoprevention. Toxicol Appl Pharmacol, 244, 66-76.
DOI
ScienceOn
|
17 |
Jeong WS, M Jun, A N. Kong (2006). Nrf2: a potential molecular target for cancer chemoprevention by natural compounds. Antioxid Redox Signal, 8, 99-106.
DOI
ScienceOn
|
18 |
Konstantinopoulos PA, Spentzos D, Fountzilas E, et al (2011). Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer. Cancer Res, 71, 5081-9.
DOI
|
19 |
Lin CW, Wu MJ, Liu IY, Su JD, Yen JH (2010). Neurotrophic and cytoprotective action of luteolin in PC12 cells through ERK-dependent induction of Nrf2-driven HO-1 expression. J Agric Food Chem, 58, 4477-86.
DOI
ScienceOn
|
20 |
Conseil G, RG Deeley, Cole SP (2005). Polymorphisms of MRP1 (ABCC1) and related ATP-dependent drug transporters. Pharmacogenet Genomics, 15, 523-33.
DOI
|
21 |
Bagli E, Stefaniotou M, Morbidelli L, et al (2004). Luteolin inhibits vascular endothelial growth factor-induced angiogenesis; inhibition of endothelial cell survival and proliferation by targeting phosphatidylinositol 3'-kinase activity. Cancer Res, 64, 7936-46.
DOI
|
22 |
Gao AM, Ke ZP, Wang JN, et al (2013). Apigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ ADM cells to doxorubicin via inhibiting PI3K/Akt/Nrf2 pathway. Carcinogenesis, 34, 1806-14.
DOI
|
23 |
Chen CC, Chu CB, Liu K J, et al (2013). Gene Expression Profiling for Analysis Acquired Oxaliplatin Resistant Factors in Human Gastric Carcinoma TSGH-S3 Cells: the Role of IL-6 Signaling and Nrf2/AKR1C Axis Identification. Biochem Pharmacol, 86, 872-87
DOI
|
24 |
Chou TC, Motzer RJ, Tong Y, Bosl GJ (1994). Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst, 86, 1517-24.
DOI
ScienceOn
|
25 |
DeNicola GM, Karreth FA, Humpton TJ, et al (2011). Oncogeneinduced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature, 475, 106-9.
DOI
ScienceOn
|
26 |
Hu X F, Yao J, Gao SG, et al (2013). Nrf2 overexpression predicts prognosis and 5-fu resistance in gastric cancer. Asian Pac J Cancer Prev, 14, 5231-5.
DOI
ScienceOn
|
27 |
Attoub S, Hassan AH, Vanhoecke B, et al (2011). Inhibition of cell survival, invasion, tumor growth and histone deacetylase activity by the dietary flavonoid luteolin in human epithelioid cancer cells. Eur J Pharmacol, 651, 18-25.
DOI
ScienceOn
|